The Technical Analyst
Select Language :
IGM Biosciences Inc [IGMS]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

IGM Biosciences Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: BUY (auto-tracking)

IGM Biosciences Inc is listed at the  Exchange

4.10% $9.65

America/New_York / 28 mar 2024 @ 16:00


IGM Biosciences Inc: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 567.29 mill
EPS: -4.71
P/E: -2.05
Earnings Date: May 09, 2024
SharesOutstanding: 58.79 mill
Avg Daily Volume: 0.294 mill
RATING 2024-03-28
B
Neutral
RATINGS
Rating CashFlow: Neutral
Return On Equity: Strong Sell
Return On Asset: Sell
DE: Buy
P/E: Sell
Price To Book: Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -2.05 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.35x
Company: PE -2.05 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$0.753
(-92.19%) $-8.90
Date: 2024-03-28
Expected Trading Range (DAY)

$ 8.29 - 11.01

( +/- 14.10%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-03-26 Schwarzer Fred Buy 38 583 Common Stock
2024-03-26 Keyt Bruce Buy 24 019 Common Stock
2024-03-28 Baker Bros. Advisors Lp Buy 89 407 Common Stock
2024-03-27 Baker Bros. Advisors Lp Buy 8 439 Common Stock
2024-03-27 Baker Bros. Advisors Lp Buy 17 101 Common Stock
INSIDER POWER
83.60
Last 99 transactions
Buy: 2 483 925 | Sell: 237 828

Forecast: 16:00 - $9.62

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $9.62
Forecast 2: 16:00 - $9.62
Forecast 3: 16:00 - $9.62
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $9.65 (4.10% )
Volume 0.234 mill
Avg. Vol. 0.294 mill
% of Avg. Vol 79.58 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for IGM Biosciences Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for IGM Biosciences Inc

RSI

Intraday RSI14 chart for IGM Biosciences Inc

Last 10 Buy & Sell Signals For IGMS

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:34buy$13.06N/AActive
Profile picture for
            IGM Biosciences Inc

IGMS

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Last 10 Buy Signals

Date Signal @
DAOUSDMar 29 - 01:54$1.742
BONDUSDMar 29 - 01:534.97
NOSUSDMar 29 - 01:494.05
FOLDUSDMar 29 - 01:4824.92
PENDLEUSDMar 29 - 01:434.34
SANTOSUSDMar 29 - 01:437.66
OGUSDMar 29 - 01:435.90
ENSUSDMar 29 - 01:4122.01
TWTUSDMar 29 - 01:40$1.420
KSMUSDMar 29 - 01:38$48.53

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.